SAN FRANCISCO, Nov. 7, 2017 /PRNewswire/ -- Audentes
Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company
focused on developing and commercializing gene therapy products for
patients living with serious, life-threatening rare diseases, will
host a conference call to report its third quarter 2017 financial
results and provide a corporate update on Tuesday, November 14, 2017.
The conference call will be held at 4:30
p.m. ET, after the market closes. To access a live
webcast of the conference call, please visit the Investor and Media
page of the Audentes website at www.audentestx.com.
Alternatively, please call 1-833-659-8620 (U.S.) or 1-409-767-9247
(international) and dial the conference ID 2599735 to access the
call.
A replay of the webcast will be available on the Audentes
website for approximately 30 days.
About Audentes Therapeutics, Inc.
Audentes
Therapeutics (Nasdaq: BOLD) is a biotechnology company focused
on developing and commercializing gene therapy products for
patients living with serious, life-threatening rare diseases.
We have four product candidates in development, AT132 for the
treatment of X-Linked Myotubular Myopathy (XLMTM), AT342 for the
treatment of Crigler-Najjar Syndrome, AT982 for the treatment of
Pompe disease, and AT307 for the treatment of the CASQ2 subtype of
Catecholaminergic Polymorphic Ventricular Tachycardia
(CASQ2-CPVT). We are a focused, experienced and passionate
team committed to forging strong, global relationships with the
patient, research and medical communities.
For more information regarding Audentes, please
visit www.audentestx.com.
Audentes Contacts:
Investor Contact:
Andrew Chang, Investor Relations
415.818.1033
ir@audentestx.com
Media Contact:
Paul Laland
415.519.6610
media@audentestx.com
View original content with
multimedia:http://www.prnewswire.com/news-releases/audentes-therapeutics-to-release-third-quarter-2017-financial-results-and-provide-corporate-update-on-tuesday-november-14-2017-300550735.html
SOURCE Audentes Therapeutics, Inc.